Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

13.07
-0.5400-3.97%
Post-market: 13.100.0300+0.23%19:58 EDT
Volume:5.65M
Turnover:74.04M
Market Cap:1.29B
PE:-2.24
High:13.59
Open:13.56
Low:12.88
Close:13.61
52wk High:39.89
52wk Low:12.88
Shares:98.32M
Float Shares:80.72M
Volume Ratio:1.21
T/O Rate:7.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-4.42
PE(LYR):-2.24

Loading ...

Ultragenyx Pharmaceutical (RARE) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 20

FDA Grants Ultragenyx Accelerated Approval for Genglycos in GSDIa Patients 8 and Older

Reuters
·
Aug 20

Ultragenyx announces FDA accelerated approval of Genglycos

TIPRANKS
·
Aug 20

Ultragenyx's Gene Therapy for Rare Metabolic Disorder Secures US FDA Nod

Reuters
·
Aug 20

Ultragenyx Pharmaceutical - Genglycos to be Available Through National Network of Qualified Treatment Centers

THOMSON REUTERS
·
Aug 20

Ultragenyx Announces U.S. FDA Approval of Genglycos™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (Gsdia)

THOMSON REUTERS
·
Aug 20

Ultragenyx (RARE) Stock Could Stay Fully Priced On Setrusumab Regulatory Talks

Simply Wall St.
·
Aug 19

Binance flags 5 tokens as possible delisting risks

cryptonews
·
Aug 12

Ultragenyx Pharmaceutical: Will Grant Esjay a Non-Exclusive, Royalty-Free License to Market Its Generic Version of Dojolvi Beginning January 1, 2033

THOMSON REUTERS
·
Aug 11

Ultragenyx Pharmaceutical - Co and Bri Settle Dojolvi Patent Litigation with Esjay Pharma - SEC Filing

THOMSON REUTERS
·
Aug 11

Ultragenyx Settles Dojolvi Patent Suit, Grants Esjay Generic Entry from 2033

Reuters
·
Aug 11

UK's Mereo BioPharma Q2 Loss Narrows on Lower R&D Spending

Reuters
·
Aug 11

Binance to Delist Five Cryptocurrencies: Details

utoday
·
Aug 11

Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI

TIPRANKS
·
Aug 10

Ultragenyx Pharma Price Target Maintained with a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 10

How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) Q2 Revenue Gain And Narrower Net Loss

Simply Wall St.
·
Aug 10

Analysts Have Conflicting Sentiments on These Healthcare Companies: Stevanato Group (STVN), Ultragenyx Pharmaceutical (RARE) and PROCEPT BioRobotics (PRCT)

TIPRANKS
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05

Ultragenyx price target raised to $81 from $79 at Canaccord

TIPRANKS
·
Aug 05

Ultragenyx Pharmaceutical Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05